Market Reports Center One Stop Market Reaserch Shop Large Cap Pharma Us & Eu Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology. Bristol-Myers’ s with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1 drug. Along with Bristol, there's Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field. Browse Detail Report With TOC @ https://marketreportscenter.com/reports/139678/large-cap-pharma-us-eu-outlook-2016-maximizing The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. AntiInfective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche’ in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer’ s disease, Parkinson’ s, ALS, Neuroimmunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain). Celgene (CELG) keeps capitalizing on its strength in hematology and operational excellence to build global standards of care in the segments of Oncology and Inflammation & Immunology (I&I). Gilead, a prominent player in Hepatitis C therapy areas is looking to expand its learning in Liver disease for another high unmet need of Nonalcoholic Steatohepatitis (NASH), while its Oncolgy segment failed to make any major impact other than approved drug Zydelig. First – in-class mechanisms like anti-PD1, Market Reports Center One Stop Market Reaserch Shop anti-PCSK9 and CDK inhibitors continue to get attraction by large cap pharma companies. Biotech and pharmaceutical companies pursue targeted and specialized therapies – more than 25% (45 new drugs approval vs. 44 in 2014) of drugs approved by FDA in 2015 are Personalized Medicines. Global Biopharmaceutical Outlook 2016-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry. Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/139678 Table of Content AMGEN : Focus On New Biologics For Larger Market And Biosimilar to Offset Own Losses! -Figure 1 Amgen IMPACT OF BLINATUMOMAB TREATMENT IN MRD+ ALL PTS -Key Pipeline Products and Development -Key Acquisitions and Partnership in 2015 - AMGN’ s Commercial Strategy -KEY MILESTONES Biogen Idec :Growth from Tecfidera and Newly Launched Products! -MARKETED PRODUCTS – TO GAIN STRENGTH BASED ON NEW DATA -PIPELINE TO WATCH IN 2016/2017 -KEY MILESTONES -Annexure I : Biogen Idec MULTIPLE SCLEROSIS – INJECTABLE DRUGS DATA COMPARISON Annexure II : Biogen Idec MULTIPLE SCLEROSIS – ORAL DRUGS DATA COMPARISON CELGENE : Innovative Strategies for Long Term Gains KEY MILESTONES -Development In Multiple Myeloma Franchise: Strengthening Pipeline and Sales -Inflammation – Pipeline maturing beyond OTEZLA -Other Products in Mid stage for Long Term Growth Celegene: Table 1 RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RECENTLY APPROVED – DATA COMPARISON GILEAD SCIENCES Poised to Emerge as a Leader in HCV Treatment! Table 1 Gilead Sciences DEVELOPMENT PIPELINE Table 2 Market Reports Center One Stop Market Reaserch Shop Gilead Sciences DATA FROM ASTRAL -1 STUDY Table 3 Gilead Sciences DATA FROM ASTRAL-4 STUDY - GILD has multiple programs running in late stage PhII/PhIII chronic HBV pts -Liver Disease – Non-alcoholic Hepatosteatosis (NASH) - Inflammation/Respiratory Pipeline - ACQUISITIONS IN THE LAST ONE YEAR KEY MILESTONES AstraZeneca: Late Stage Pipeline maturing; Focused development on Respiratory, Psoriasis and anti-PD1 will support long term growth -Table 1 AstraZeneca COMPETITIVE LANDSCAPE OF BIOLOGICS IN SEVERE ASTHMA - Table 2 AstraZeneca ORR BY IFN? AND PD-L1 STATUS TABLE 3 AstraZeneca DURVALUMAB CLINICAL DEVELOPMENT PROGRAMS -COMMERCIAL ADVANCEMENT- KEY MILESTONES TABLE GlaxoSmithKline : Reliance On Low Margin Consumer Health And Vaccines; Unable To Revive Respiratory Franchise -PIPELINE ANALYSIS – HIV/INFECTIOUS DISEASE - HCV AND HBV PIPELINE – TOO EARLY TO COMMENT - PIPELINE ANALYSIS: RESPIRATORYPIPELINE ANALYSIS – RESPIRATORY -Other Biologics in Asthma Pipeline: - RESPIRATORY DISEASE - COPD -RESPIRATORY R&D BEYOND ASTHMA AND COPD - PIPELINE ANALYSIS – VACCINES - PIPELINE ANALYSIS – IMMUNO-INFLAMMATION - PIPELINE ANALYSIS – RARE DISEASE - PIPELINE ANALYSIS – ONCOLOGY - KEY MILESTONES Merck & Co : Anti-PD1 and HCV will remain growth drivers - going forward! KEY POTENTIAL CATALYSTS FOR 2016 -Table 1 Merck To Get Discount On The Report @ https://marketreportscenter.com/request-discount/139678 Market Reports Center One Stop Market Reaserch Shop About Us: Market Reports Centeris an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable. Market Reports Center currently has more than 1,20,000 plus titles and 30+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies. Contact Information: Sam Collins Market Reports Center 1-646-883-3044 (US) [email protected] https://marketreportscenter.com http://marketreportscenter.blogspot.in/

The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm.